Piper Sandler analyst Adam Maeder views the FDA approval of Abbott’s (ABT) Proclaim XR spinal cord stimulation system for the treatment of painful diabetic neuropathy as an "incremental headwind" to Nevro (NVRO). The analyst believes Abbott should be well positioned in painful diabetic neuropath segment of the spinal cord stimulation market given its sizeable presence in both pain stim and diabetes. However, Nevro should have an advantage in the field given the "highly compelling" results demonstrated in its SENZA-PDN study, Piper contends. The firm keeps an Underweight rating on Nevro with a $37 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO:
- Nevro price target lowered to $37 from $38 at Piper Sandler
- Nevro downgraded to Neutral from Buy at Citi
- Nevro price target lowered to $37 from $43 at Wells Fargo
- Nevro 2023 guidance looks ‘a touch lofty,’ says Piper Sandler
- Nevro falls -8.6%
Questions or Comments about the article? Write to editor@tipranks.com